Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing novel, plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal distress, specifically addressing urgent, unmet medical needs. Their lead human product, Mytesi® (crofelemer), is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company, along with its subsidiary Napo Pharmaceuticals, is also actively developing crofelemer for other indications, including cancer therapy-related diarrhea and rare diseases. Additionally, Jaguar Health, through its Napo Animal Health division, develops and commercializes animal health products.
The San Francisco headquarters serves as the primary center for Jaguar Health's executive leadership, corporate strategy, financial operations, investor relations, research and development oversight, and global business development initiatives.
Located in San Francisco's Financial District, the headquarters provides a strategic position within a dynamic business ecosystem. As a tenant in a multi-use office building, specific unique architectural highlights of their suite are not publicly emphasized, but the location offers modern office amenities.
The work culture at Jaguar Health is likely dynamic and mission-driven, characteristic of a smaller pharmaceutical company. It probably fosters innovation, scientific collaboration, and a strong focus on bringing patient-centric solutions for gastrointestinal health to market. Employees are likely dedicated to the company's unique approach of developing plant-based medicines.
The San Francisco headquarters offers Jaguar Health proximity to leading research institutions, a rich talent pool in biotech and pharma, and access to the financial community essential for funding and partnerships in the life sciences sector.
Jaguar Health maintains a global outlook, primarily driven by its U.S. operations and its European subsidiary, Napo EU S.r.l., in Milan, Italy. Its global functions include international clinical trial management, pursuing regulatory approvals in various regions, intellectual property management, and establishing strategic partnerships for development and commercialization worldwide. The company aims to address unmet medical needs in gastrointestinal health on a global scale for both humans and animals.
200 Pine Street, Suite 400
San Francisco
California
USA
Address: Via San Gregorio 34, 20124 Milan, Italy (Napo EU S.r.l.)
To serve as the European hub for clinical, regulatory, and commercial activities, enabling Jaguar Health to navigate the European pharmaceutical landscape, engage with key opinion leaders, and expand the reach of its gastrointestinal health solutions to patients and animals in Europe.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Jaguar Health' leadership includes:
Jaguar Health has been backed by several prominent investors over the years, including:
Over the past 12 months, Jaguar Health has strategically expanded its executive team with key appointments in commercial, medical, and clinical development roles, reflecting its focus on advancing its product pipeline and commercial efforts. No high-profile executive departures have been publicly announced during this period.
Discover the tools Jaguar Health uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Jaguar Health primarily uses the email format combining the first initial of an employee's name followed by their last name, at the company's domain. This is a common pattern for professional communication within the organization.
[first_initial][last]@jaguarhealth.com
Format
lconte@jaguarhealth.com
Example
85%
Success rate
Business Wire • May 30, 2024
Jaguar Health announced the publication of study results demonstrating the positive effects of its crofelemer product candidate on stool consistency and dehydration in water buffalo calves with watery diarrhea. The findings were published in the Journal of Dairy Science Communications....more
GlobeNewswire • May 15, 2024
Jaguar Health released its financial results for the first quarter ended March 31, 2024. The company also provided a business update, highlighting advancements in its Mytesi commercial activities and progress across its pipeline of crofelemer-based product candidates....more
PR Newswire • May 15, 2024
Jaguar Health appointed William H. Cable, M.D. as its new Senior Vice President, Head of Clinical Development. Dr. Cable brings extensive experience in pharmaceutical development and is expected to lead and expand the company's clinical programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Jaguar Health, are just a search away.